目次

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperinsulinemia - Overview
Hyperinsulinemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperinsulinemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperinsulinemia - Companies Involved in Therapeutics Development
AmideBio, LLC
Crinetics Pharmaceuticals Inc
Eiger BioPharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
PegBio Co Ltd
Rezolute Inc
Seneb BioSciences Inc
Xeris Biopharma Holdings Inc
Zealand Pharma AS
Hyperinsulinemia - Drug Profiles
ABG-023 - Drug Profile
Product Description
Mechanism Of Action
avexitide acetate - Drug Profile
Product Description
Mechanism Of Action
CRN-04777 - Drug Profile
Product Description
Mechanism Of Action
dasiglucagon - Drug Profile
Product Description
Mechanism Of Action
exendin-(9-39) - Drug Profile
Product Description
Mechanism Of Action
glucagon - Drug Profile
Product Description
Mechanism Of Action
HM-15136 - Drug Profile
Product Description
Mechanism Of Action
PB-722 - Drug Profile
Product Description
Mechanism Of Action
RZ-358 - Drug Profile
Product Description
Mechanism Of Action
SNB-2401 - Drug Profile
Product Description
Mechanism Of Action
Hyperinsulinemia - Dormant Projects
Hyperinsulinemia - Discontinued Products
Hyperinsulinemia - Product Development Milestones
Featured News & Press Releases
Nov 28, 2022: Crinetics Pharmaceuticals provides update on CRN04777 Program
Oct 06, 2022: Innovation passport granted for CRN04777 for the treatment of congenital hyperinsulinism
Oct 04, 2022: AmideBio awarded SBIR phase IIb grant to support pre-clinical development of its long-acting stable glucagon analog for the treatment of hyperinsulinism
Sep 19, 2022: Zealand Pharma presents data from phase 3 trial of dasiglucagon in congenital hyperinsulinism at the 60th Annual ESPE Meeting
Sep 17, 2022: Rezolute announces presentation at the 60th Annual ESPE Meeting
Jun 13, 2022: Eiger BioPharmaceuticals announces new data supporting broader potential of avexitide in patients with post-bariatric hypoglycemia and hyperinsulinemic hypoglycemia after gastrointestinal surgeries
May 19, 2022: Zealand Pharma announces positive results from phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI)
May 01, 2022: Rezolute announces positive data from its phase 2b (RIZE) Study of RZ358 in patients with congenital hyperinsulinism
Apr 26, 2022: Rezolute announces RZ358 Phase 2b (RIZE Study) topline data to be unveiled at Pediatric Endocrine Society 2022 Annual Meeting
Mar 30, 2022: Crinetics Pharmaceuticals reports positive top-line results from CRN04777 phase 1 study multiple-ascending dose cohorts
Sep 22, 2021: Rezolute presents results from two-week natural history study in congenital hyperinsulinism patients on standard of care therapies at ESPE 2021
Sep 15, 2021: Crinetics Pharmaceuticals’ oral SST5 agonist CRN04777 demonstrated pharmacologic proof-of-concept with strong dose-dependent suppression of insulin secretion in phase 1 single ascending dose study
Sep 09, 2021: Rezolute announces initiation of dosing in the second cohort of its phase 2b trial of RZ358 for congenital hyperinsulinism
Feb 03, 2021: Crinetics Pharmaceuticals advances CRN04777 for congenital hyperinsulinism into phase 1 study
Jan 21, 2021: Hanmi Pharmaceutical’s innovative new drug HM15136 receives FDA phase 2 clinical trial approval
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hyperinsulinemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hyperinsulinemia - Pipeline by AmideBio, LLC, 2022
Hyperinsulinemia - Pipeline by Crinetics Pharmaceuticals Inc, 2022
Hyperinsulinemia - Pipeline by Eiger BioPharmaceuticals Inc, 2022
Hyperinsulinemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Hyperinsulinemia - Pipeline by PegBio Co Ltd, 2022
Hyperinsulinemia - Pipeline by Rezolute Inc, 2022
Hyperinsulinemia - Pipeline by Seneb BioSciences Inc, 2022
Hyperinsulinemia - Pipeline by Xeris Biopharma Holdings Inc, 2022
Hyperinsulinemia - Pipeline by Zealand Pharma AS, 2022
Hyperinsulinemia - Dormant Projects, 2022
Hyperinsulinemia - Discontinued Products, 2022

List of Figures
Number of Products under Development for Hyperinsulinemia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022